Huadong Medicine (SHE:000963) will conduct clinical trials on the drug HDP-101 after receiving approval from Chinese drug regulator National Medical Products Administration, according to a Wednesday disclosure on the Shenzhen Stock Exchange.
The drug will be tested as a treatment against B-cell maturation antigen-positive clonal hematologic diseases like relapsed or refractory multiple myeloma, the pharmaceutical company said.
Shares of the company fell more than 1% at the close.
Price (RMB): ¥32.76, Change: ¥-0.45, Percent Change: -1.36%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments